Indian Journal of Research in Homeopathy

EDITORIAL
Year
: 2021  |  Volume : 15  |  Issue : 2  |  Page : 75--76

Second wave of COVID-19: Steps and future vision


Anil Khurana 
 Director General, CCRH

Correspondence Address:
Dr. Anil Khurana
Director General, CCRH




How to cite this article:
Khurana A. Second wave of COVID-19: Steps and future vision.Indian J Res Homoeopathy 2021;15:75-76


How to cite this URL:
Khurana A. Second wave of COVID-19: Steps and future vision. Indian J Res Homoeopathy [serial online] 2021 [cited 2021 Oct 27 ];15:75-76
Available from: https://www.ijrh.org/text.asp?2021/15/2/75/319610


Full Text



India has recently seen a devastating second wave of the COVID-19 pandemic, with a record high of over 414,000[1] new cases on 6th May 2021. The unprecedented wave hit the country in several ways, with many states imposing complete or partial lockdowns to check further spread, their people struggling to come to terms with magnitude of the wave, and most unfortunately, many families losing their dear ones to COVID-19. The entire world was hoping and praying for India's recovery from this biggest jolt ever of severe acute respiratory syndrome coronavirus-2 virus epidemic.

In such testing times, many homoeopathic doctors volunteered to help the COVID positive cases and suspected cases by reaching out to provide them free consultations, and homoeopathic medicines. Understanding the need of the hour, Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) released Guidelines for Homoeopathy Practitioners for Prophylaxis and Symptomatic Management of Home-isolated COVID-19 patients, as a reference source for such practitioners who wanted to be of service to the nation and its people.[2] Ministry also released a countrywide 'AYUSH COVID-19 Counselling Helpline' for people who aimed to use any of the AYUSH systems for prevention/treatment/post-infection recovery from COVID-19.[3] The medical (AYUSH) experts on the other end of line provide desired counselling to the callers, advise feasible remedies, as well as guide them about the availability of nearby AYUSH facilities.

Mucormycosis came up as an eminent post-COVID complaint, and soon caught the attention of the medical fraternity, with many reporting on ways to treat, and prevent the condition.[4] Ministry of AYUSH also released an information document for Homoeopathy practitioners for symptomatic management of suspected and diagnosed cases of mucormycosis.[5]

Around the world, views are being shared by Homoeopathy practitioners to consider clinical repurposing of the homoeopathic medicines in the treatment of COVID-19 as an adjuvant or stand-alone to help reduce costs and improve patient recovery.[6] The world is indeed eager to see the published outcomes of some of the clinical trials that took place in India, and other parts of the world during the first wave of the pandemic, to push for this approach more assertively.

In this issue, we feature an indigenous fragmentarily proved drug, Cuprum aceticum. Since its inception, the Central Council for Research in Homoeopathy (CCRH) has adopted the Drug Proving Research Program as one of its primary research areas. The pathogenetic response elicited by Cuprum aceticum in a multicentric, double-blind, randomised, placebo-controlled proving trial is analysed and presented in this issue, with the intent to expand the scope of its use and further clinical verification.[7] Another drug for which CCRH had conducted a proving in the yesteryears was Gymnema sylvestre, which is known to have an important place among antidiabetic medicinal plants.[8] A preclinical study eliciting the response of streptozotocin-induced diabetic rats to homoeopathic preparations of Gymnema sylvestre in mother tincture form, 30C and 200C potencies, is also presented.[9]

The research activities of CCRH also cover another key area which is drug standardisation. The Council has been undertaking studies on pharmacognostical, physico-chemical and pharmacological aspects of numerous drugs. One such drug is Rumex acetosella, whose physicochemical standardization and its comparison with Rumex crispus are presented in this issue.[10]

One of the uniqueness of Homoeopathy is the varied clinical approaches used in practice while adhering to the basic principles of Homoeopathy. A study compares the effect of individualised homoeopathic medicine administered based on totality of symptoms vis-à-vis personality in patients suffering from knee osteoarthritis.[11]

Another interesting study in this issue presents a plausible list of homoeopathic medicines that might help in the treatment or serve as genus epidemicus of COVID-19 disease.[12]

Three evidence-based case reports on the successful homoeopathic treatment of wrist ganglion and two on nephrolithiasis are also presented in this issue.[13],[14],[15]

References

1India - COVID-19 Overview - Johns Hopkins. Available from: https://coronavirus.jhu.edu/region/india. [Last accessed on 2021 Jun 10].
2Ministry of Ayush. Government of India. Guidelines for Homoeopathy Practitioners for Prophylaxis and Symptomatic Management of Home Isolated COVID-19 Patients. Available from: https://www.ayush.gov.in/docs/CCRH-%20Revised%20Guidelines%20for%20Homoeopathy%20Practitioners%20for%20Prophylaxis%20and%20Symptomatic%20Management%20of%20COVID-19%20 Patients%20in%20Home%20Isolation.pdf. [Last accessed on 2021 Jun 10].
3Countrywide “AYUSH COVID -19 Counselling Helpline” Operationalized. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1720519. [Last accessed on 2021 Jun 10].
4Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev 2021. doi: https://doi.org/10.1016/j.dsx.2021.05.019.
5Ministry of Ayush. Government of India. Information for Homoeopathy Practitioners for Symptomatic Management of Suspected and Diagnosed Cases of Mucormycosis. Available from: https://www.ayush.gov.in/docs/Information%20for%20homoeopathic%20management%20of%20Mucormycosis-reg.pdf. [Last accessed on 2021 Jun 10].
6Varanasi R, Nayak D, Khurana A. Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India. Homeopathy. 2021. doi: 10.1055/s-0041-1725988. Epub ahead of print.
7Mehra P, Mahajan A, Vichitra AK, Rajakumar BS, Singh JP, Banoth K, et al. Homoeopathic pathogenetic trial of Cuprum aceticum: A multicentric, double-blind, randomized, placebo controlled trial. Indian J Res Homoeopathy 2021;15:77-94.
8Rakshit G, Singh JP, Pathak SD, Banoth CK, Chandra PK, Rajpal, et al. A multi-centric double-blind randomized homoeopathic pathogenetic trial of Gymnema sylvestre. Indian J Res Homoeopathy 2013;7:9-21.
9Shukla A, Mhaisker IU, Rampal KG, Sheshala R. In vivo study of homoeopathic preparation of Gymnema sylvestre mother tincture, 30c and 200c on streptozotocin-induced diabetic rats. Indian J Res Homoeopathy 2021;15:95-102.
10Biswas B, Dey N, Kumar GV, Arya R, Khurana A. Physicochemical standardisation of the homoeopathic drug Rumex acetosella and its comparison with another homoeopathic drug, Rumex crispus. Indian J Res Homoeopathy 2021;15:113-22.
11Kumar NR, Iyer NH. An observational study on the effect of individualised homoeopathic medicine administered based on totality of symptoms vis-à-vis personality in cases of osteoarthritis knee. Indian J Res Homoeopathy 2021;15:103-10.
12Escalante HM, Hasan N, Delgado AG, Soto SG, Vivas JM. A group of homoeopathic medicines for COVID--19: A systematic review of clinical features. Indian J Res Homoeopathy 2021;15:123-36.
13Nath A, Palit DK. Homeopathic management of wrist ganglion: A case series. Indian J Res Homoeopathy 2021;15:137-46.
14Gautam P. A case report of hyperuricaemia with nephrolithiasis treated with homoeopathy. Indian J Res Homoeopathy 2021;15:147-54.
15Rai S, Vineetha KR. A 15-mm urinary calculus expelled with homoeopathic medicine - A case report. Indian J Res Homoeopathy 2021;15:155-61.